FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2324883330> ?p ?o ?g. }

• W2324883330 endingPage "124" @default.
• W2324883330 startingPage "93" @default.
• W2324883330 abstract "Oral single-dose and 13-week repeat-dose toxicity studies of (±)-4-ethylamino- 1, 1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride (RCC-36), an active metabolite of (±)-4-diethylamino-1, 1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a new drug for the treatment of urinary frequency and incontinence, were conducted in male and female Sprague-Dawley rats. In the single-dose toxicity study, rats were given the drug at doses of 0 (contol), 400, 600, 900, 1350 and 2030 mg/kg. In the 13-week repeat-dose toxicity study, rats were given the drug for 13 weeks at doses of 0 (control), 3, 30 and 300 mg/kg. After discontinuation of the treatment, a 5-week recovery test was also conducted. In the single-dose toxicity study, death occurred in the 600 mg/kg group and over, and LD%lt;50> values were 735 mg/kg in both sexes. The major clinical signs observed following the administration of this drug were mydriasis, salivation, decreased spontaneous locomotor activity, ataxic gait, lacrimation and urorrhea in the 400 mg/kg group and over hypopnea and soft feces in the 600 mg/kg group and over. In addition, prone or lateral position and tonic or clonic convulsion were observed in the dead animals. Rats showed a decrease in body weight or a suppression of its weight gain in the 400 mg/kg group and over. Macroscopic findings in the dead animals were congestion in lung and retention of foamy mucinous fluid in trachea. The animals alive showed no abnormalities attributable to the treatment. In the 13-week repeat-dose toxicity study, 13 cases of death occurred in the 300 mg/kg group. Main pathological findings in these cases were congestion and edema in lung. Mydriasis was seen in the 30 mg/kg group and over. Lacrimation, salivation, wheezing, emaciaion wasting and unkempt fur were seen in the 300 mg/kg. A suppression of body weight gain and a decrease in food consumption were observed in the 300 mg/kg group. An increase in water consumption was seen in the 30 and 300 mg/kg groups. Ophthalmologic examination confirmed the mydriasis in the 30 mg/kg group and over. Urinalysis showed an increase in urine volume and a decrease in Na+ excretion in the 30 and 300 mg/kg groups and decreases in K+ and Cl- excretions in the 300 mg/kg group. Hematological examination showed decreases in hemoglobin, hematocrit, MCV and MCH, and an increase in MCHC in the 300 mg/kg group. Blood chemical examination showed decreases in triglyceride and glucose, and an increase in total protein in the 300 mg/kg group. Pathological examination disclosed hepatocellular hypertrophy associated with hyperplasia of smooth-ER, a decrease in number of glycogen granules and an increase in number of lipofuscin in the 300 mg/kg group. Stimulated thyroid follicles were seen in the 300 mg/kg/group. In kidney, an increase in number of hyaline droplets in the proximal tubular epithelium, in which lysosomes and dense bodies were increased, was observed in the 300 mg/kg group. Dense bodies were increased also in the glomerular epithelium. In this dose group, adrenocortical hypertrophy was also observed. The recovery test showed that the above-mentioned changes were satisfactorily reversible or the degree and frequency of these changes were lowered. No treatment-related effects were seen in the 3 mg/kg group. These results show that the NOAEL (no observed adverse effect level) of RCC-36 is 3 mg/kg for 13-week oral toxicity in rats." @default.
• W2324883330 created "2016-06-24" @default.
• W2324883330 creator A5000782695 @default.
• W2324883330 creator A5004025326 @default.
• W2324883330 creator A5006368012 @default.
• W2324883330 creator A5017545155 @default.
• W2324883330 creator A5022370677 @default.
• W2324883330 creator A5026437352 @default.
• W2324883330 creator A5034807685 @default.
• W2324883330 creator A5041661862 @default.
• W2324883330 date "1997-01-01" @default.
• W2324883330 modified "2023-09-26" @default.
• W2324883330 title "ORAL SINGLE-DOSE AND 13-WEEK REPEAT-DOSE TOXICITY STUDIES OF RCC-36, THE ACTIVE METABOLITE OF (±)-4-DIETHYLAMINO-1, 1-DIMETHYLBUT-2-YN-1-YL 2-CYCLOHEXYL-2-HYDROXY-2-PHENYLACETATE MONO-HYDROCHLORIDE MONOHYDRATE(NS-21), A NOVEL DRUG FOR URINARY FREQUENCY AND INCONTINENCE, IN RATS" @default.
• W2324883330 cites W1879996397 @default.
• W2324883330 cites W1991788172 @default.
• W2324883330 cites W2012757283 @default.
• W2324883330 cites W2072831880 @default.
• W2324883330 cites W31515455 @default.
• W2324883330 doi "https://doi.org/10.2131/jts.22.supplementi_93" @default.
• W2324883330 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9170604" @default.
• W2324883330 hasPublicationYear "1997" @default.
• W2324883330 type Work @default.
• W2324883330 sameAs 2324883330 @default.
• W2324883330 citedByCount "1" @default.
• W2324883330 crossrefType "journal-article" @default.
• W2324883330 hasAuthorship W2324883330A5000782695 @default.
• W2324883330 hasAuthorship W2324883330A5004025326 @default.
• W2324883330 hasAuthorship W2324883330A5006368012 @default.
• W2324883330 hasAuthorship W2324883330A5017545155 @default.
• W2324883330 hasAuthorship W2324883330A5022370677 @default.
• W2324883330 hasAuthorship W2324883330A5026437352 @default.
• W2324883330 hasAuthorship W2324883330A5034807685 @default.
• W2324883330 hasAuthorship W2324883330A5041661862 @default.
• W2324883330 hasBestOaLocation W23248833301 @default.
• W2324883330 hasConcept C118552586 @default.
• W2324883330 hasConcept C126322002 @default.
• W2324883330 hasConcept C185592680 @default.
• W2324883330 hasConcept C2776897752 @default.
• W2324883330 hasConcept C2777010014 @default.
• W2324883330 hasConcept C2777477808 @default.
• W2324883330 hasConcept C2778186239 @default.
• W2324883330 hasConcept C2778715236 @default.
• W2324883330 hasConcept C2779109636 @default.
• W2324883330 hasConcept C29730261 @default.
• W2324883330 hasConcept C42219234 @default.
• W2324883330 hasConcept C55493867 @default.
• W2324883330 hasConcept C71924100 @default.
• W2324883330 hasConcept C98274493 @default.
• W2324883330 hasConceptScore W2324883330C118552586 @default.
• W2324883330 hasConceptScore W2324883330C126322002 @default.
• W2324883330 hasConceptScore W2324883330C185592680 @default.
• W2324883330 hasConceptScore W2324883330C2776897752 @default.
• W2324883330 hasConceptScore W2324883330C2777010014 @default.
• W2324883330 hasConceptScore W2324883330C2777477808 @default.
• W2324883330 hasConceptScore W2324883330C2778186239 @default.
• W2324883330 hasConceptScore W2324883330C2778715236 @default.
• W2324883330 hasConceptScore W2324883330C2779109636 @default.
• W2324883330 hasConceptScore W2324883330C29730261 @default.
• W2324883330 hasConceptScore W2324883330C42219234 @default.
• W2324883330 hasConceptScore W2324883330C55493867 @default.
• W2324883330 hasConceptScore W2324883330C71924100 @default.
• W2324883330 hasConceptScore W2324883330C98274493 @default.
• W2324883330 hasIssue "SupplementI" @default.
• W2324883330 hasLocation W23248833301 @default.
• W2324883330 hasLocation W23248833302 @default.
• W2324883330 hasOpenAccess W2324883330 @default.
• W2324883330 hasPrimaryLocation W23248833301 @default.
• W2324883330 hasRelatedWork W2023487034 @default.
• W2324883330 hasRelatedWork W2066870155 @default.
• W2324883330 hasRelatedWork W2076052464 @default.
• W2324883330 hasRelatedWork W2087832256 @default.
• W2324883330 hasRelatedWork W2088203456 @default.
• W2324883330 hasRelatedWork W2112727823 @default.
• W2324883330 hasRelatedWork W2324883330 @default.
• W2324883330 hasRelatedWork W2466043692 @default.
• W2324883330 hasRelatedWork W3165821010 @default.
• W2324883330 hasRelatedWork W2785926487 @default.
• W2324883330 hasVolume "22" @default.
• W2324883330 isParatext "false" @default.
• W2324883330 isRetracted "false" @default.
• W2324883330 magId "2324883330" @default.
• W2324883330 workType "article" @default.